support@biotechpeptides.com
Research in BPC-157 and The Digestive and Nervous Systems

Research in BPC-157 and The Digestive and Nervous Systems

by | Jan 17, 2023 | Research

BPC-157 is a pentadecapeptide made of 15 amino acids and bears the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, and a molecular formula of C62H98N16O22. This is a fully synthetic peptide with a sequence not known to occur in nature. However, it is often termed a “gut peptide,” as it is suggested to have similar structure and properties to other gastroprotective peptides found in gastric juice.

According to the patent, the peptide’s production is fully synthetic and derived from various organic and inorganic bases. BPC stands for ‘Body Protection Compound.’ It appears to be relatively stable in stomach acid compared to other peptides.

Animal studies indicate the peptide’s potential to modulate the healing of various tissues, including tendons, joints, nerves, the intestinal tract, and skin. BPC-157 likely works via various pathways, including anti-inflammatory action, modulated nitric oxide synthesis, increased growth factor synthesis, and activation of cells involved in tissue repair.

Featured Product

BPC-157 (5mg & 10mg)
 

Research

 

BPC-157 Peptide and the Digestive System

BPC-157 peptide is under investigation for its potential to protect against and treat ulcers in the gastrointestinal system. Animal studies suggest that the peptide has significant protective effects against compounds which are known to cause stomach ulcers.[1][2] Sikiric et al. report that “superior protection against different gastrointestinal and liver lesions and anti-inflammatory and analgesic activities were noted for pentadecapeptide BPC.” Researchers also suggest that this protective potential is likely related to the action of BPC-157 peptide on the alpha-adrenergic (e.g., catecholamine release) and dopaminergic (central) systems. Blocking the alpha-adrenergic or dopamine receptors may reduce the effectiveness of BPC-157 against ulcerations.

The peptide may also work by stimulating the synthesis of growth factors in the intestinal cells that cover the digestive system. Another laboratory study reports that BPC-157 peptide has also been suggested to stimulate the mRNA of the growth factor EGR-1.[3] As a result, experiments in rats report that BPC-157 peptide speeds up the healing of surgical injuries in the gastrointestinal system, specifically esophagogastric anastomosis healing.[4] Animal models with short-bowel syndrome also report that the peptide may help prevent weight loss and increase the ability of the bowels to absorb nutrients.[5,6] The researchers report constant weight gain and increased villus height, crypt depth, and muscle thickness of the small intestines. Furthermore, the scientists report that “BPC 157 completely ameliorated symptoms in massive intestinal resection.” Because of its interactions with various neurotransmitters, scientists have also investigated its effects on serotonin production. According to preliminary research BPC-157 may exert beneficial action on serotonin synthesis.[7]

 

BPC-157 Peptide and the Nervous System

Rat studies report that BPC-175 may significantly increase serotonin synthesis in several brain regions, including the “substantia nigra reticulata and medial anterior olfactory nucleus,” taking only 40 minutes for BPC-157 to exert these effects.[8]  One study in rats reported that BPC-157 peptide exhibited possible antidepressant characteristics when the animals were exposed to acute or chronic stress.[9]

BPC-157 peptide may also help ameliorate damage to the brain through various chemicals. According to one experiment which used cuprizone to induce brain damage and nerve demyelination like those observed in multiple sclerosis (MS), BPC-157 had potential protective action.[10] BPC-157 peptide appeared to have reduced the number of damaged cells in numerous brain regions, including the hippocampus. Another study that used a toxin to induce damage, like what is seen in Parkinson’s Disease in rodents, reports that BPC-157 may exerts protective action.[11]

 

BPC-157 Peptide and Skin, Bones, and Joints

BPC-157 peptide may have action that extend beyond the gastrointestinal and nervous systems, such as stimulating the repair of the skin tissues, bones, joints, tendons, and other tissues. These possible actions could be due to the potential of BPC-157 peptide to stimulate the formation of new blood vessels. By stimulating angiogenesis, BPC-157 may increase the supply of tissues with nutrients and growth factors.

According to one study in rats with injured limbs, the scientists noted an increase in VEGFR2 expression, which was much more significant compared to controls.[12] Hsieh et al. also noted that “BPC 157 accelerates the blood flow recovery and vessel number in rats with hind limb ischemia.”

In tendon and joint injuries, BPC-157 peptide may also speed up the recovery of connective tissues by upregulating fibroblast function. Experiments note that BPC-157 may allow tendon fibroblasts to grow and spread faster.[13] The researchers note that the effect was present only when the fibroblasts were replanted. Another experiment also reported increased wound healing potential in rats after injuries induced via surgical cuts. The researchers hypothesized that BPC-157 peptide might significantly increase the rate of injury healing when compared to the control.[14]

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Luetic K, Sucic M, Vlainic J, Halle ZB, Strinic D, Vidovic T, Luetic F, Marusic M, Gulic S, Pavelic TT, Kokot A, Seiwerth RS, Drmic D, Batelja L, Seiwerth S, Sikiric P. Cyclophosphamide induced stomach and duodenal lesions as a NO-system disturbance in rats: L-NAME, L-arginine, stable gastric pentadecapeptide BPC 157. Inflammopharmacology. 2017 Apr;25(2):255-264. doi: 10.1007/s10787-017-0330-7. Epub 2017 Mar 2. PMID: 28255738.
  2. Sikirić P, Mazul B, Seiwerth S, Grabarević Z, Rucman R, Petek M, Jagić V, Turković B, Rotkvić I, Mise S, Zoricić I, Jurina L, Konjevoda P, Hanzevacki M, Gjurasin M, Separović J, Ljubanović D, Artuković B, Bratulić M, Tisljar M, Miklić P, Sumajstorcić J. Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress. Dig Dis Sci. 1997 Mar;42(3):661-71. doi: 10.1023/a:1018880000644. PMID: 9073154.
  3. Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, Situm K, Perović D, Glojnarić I, Parnham MJ. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007 Sep 10;570(1-3):212-21. doi: 10.1016/j.ejphar.2007.05.072. Epub 2007 Jun 16. PMID: 17628536.
  4. Djakovic Z, Djakovic I, Cesarec V, Madzarac G, Becejac T, Zukanovic G, Drmic D, Batelja L, Zenko Sever A, Kolenc D, Pajtak A, Knez N, Japjec M, Luetic K, Stancic-Rokotov D, Seiwerth S, Sikiric P. Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World J Gastroenterol. 2016 Nov 7;22(41):9127-9140. doi: 10.3748/wjg.v22.i41.9127. PMID: 27895400; PMCID: PMC5107594.
  5. Sever M, Klicek R, Radic B, Brcic L, Zoricic I, Drmic D, Ivica M, Barisic I, Ilic S, Berkopic L, Blagaic AB, Coric M, Kolenc D, Vrcic H, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Dig Dis Sci. 2009 Oct;54(10):2070-83. doi: 10.1007/s10620-008-0598-y. Epub 2008 Dec 18. PMID: 19093208.
  6. Lojo N, Rasic Z, Zenko Sever A, Kolenc D, Vukusic D, Drmic D, Zoricic I, Sever M, Seiwerth S, Sikiric P. Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats. PLoS One. 2016 Sep 14;11(9):e0162590. doi: 10.1371/journal.pone.0162590. PMID: 27627764; PMCID: PMC5023193.
  7. Sikiric P, Seiwerth S, Rucman R, Kolenc D, Vuletic LB, Drmic D, Grgic T, Strbe S, Zukanovic G, Crvenkovic D, Madzarac G, Rukavina I, Sucic M, Baric M, Starcevic N, Krstonijevic Z, Bencic ML, Filipcic I, Rokotov DS, Vlainic J. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. doi: 10.2174/1570159×13666160502153022. PMID: 27138887; PMCID: PMC5333585.
  8. Tohyama Y, Sikirić P, Diksic M. Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain: alpha-methyl-L-tryptophan autoradiographic measurements. Life Sci. 2004 Dec 3;76(3):345-57. doi: 10.1016/j.lfs.2004.08.010. PMID: 15531385.
  9. Sikiric P, Separovic J, Buljat G, Anic T, Stancic-Rokotov D, Mikus D, Marovic A, Prkacin I, Duplancic B, Zoricic I, Aralica G, Lovric-Bencic M, Ziger T, Perovic D, Rotkvic I, Mise S, Hanzevacki M, Hahn V, Seiwerth S, Turkovic B, Grabarevic Z, Petek M, Rucman R. The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt’s test and chronic unpredictable stress in rats. A comparison with antidepressants. J Physiol Paris. 2000 Mar-Apr;94(2):99-104. doi: 10.1016/s0928-4257(00)00148-0. PMID: 10791689.
  10. Klicek R, Kolenc D, Suran J, Drmic D, Brcic L, Aralica G, Sever M, Holjevac J, Radic B, Turudic T, Kokot A, Patrlj L, Rucman R, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013 Oct;64(5):597-612. PMID: 24304574.
  11. Sikiric P, Marovic A, Matoz W, Anic T, Buljat G, Mikus D, Stancic-Rokotov D, Separovic J, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Ziger T, Sebecic B, Zoricic I, Turkovic B, Aralica G, Perovic D, Duplancic B, Lovric-Bencic M, Rotkvic I, Mise S, Jagic V, Hahn V. A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson’s disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine. J Physiol Paris. 1999 Dec;93(6):505-12. doi: 10.1016/s0928-4257(99)00119-9. PMID: 10672997.
  12. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, Ko YS, Wang JS, Chang VH, Pang JS. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017 Mar;95(3):323-333. doi: 10.1007/s00109-016-1488-y. Epub 2016 Nov 15. PMID: 27847966.
  13. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672.
  14. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003 Nov;21(6):976-83. doi: 10.1016/S0736-0266(03)00110-4. PMID: 14554208.
IGF-1 LR3 Peptides and Tissue Growth

IGF-1 LR3 Peptides and Tissue Growth

by | Dec 21, 2022 | Research

 
Scientists have created IGF-1 LR3 peptides by modifying the amino acid sequence of IGF-1. The new peptide has similar potential but possibly higher potency and improved stability. The LR3 in the name describes the two modifications to the IGF-1 molecule. Long R3 IGF-1, or IGF-1 LR3, is an analog of insulin-like growth factor 1 (IGF-1). IGF-1 is an anabolic peptide hormone naturally produced. Primarily, it is considered a mediator of the anabolic effects of growth hormone (HGH). Growth hormone appears to stimulate the production of IGF-1. The IGF-1 produced in the liver is released in the bloodstream and exerts anabolic effects, while the IGF-1 produced in all other tissues acts locally to stimulate growth. The first is R3 which describes the replacement of the 3rd amino acid in IGF-1 with arginine. Scientists ascribed an additional 13 amino acids to the N-terminus of the R3 IGF-1 molecule, turning it into Long R3 IGF-1. IGF-1 LR3 is an experimental peptide with potential anabolic and mitogenic effects.

 

IGF-1 LR3

Scientists developed IGF-1 analogs such as IGF-1 LR3 primarily for experiments to stimulate cell growth. IGF-1 and its analogs appear to be highly anabolic towards actively proliferating cells. They may speed up cell replication, ultimately shortening the time required to create a cell culture and use it to conduct laboratory studies.

IGF-1 LR3 works by activating IGF-1 receptors in most animal cells. Activating these anabolic receptors increases protein synthesis and tissue growth.  IGF-1 LR3 peptide appears to bind to a much lesser degree to IGF-1 proteins than other available analogs. Therefore, its affinity to the anabolic IGF-1 receptors may be much higher, and animal studies show that continuous exposure to IGF-1 LR3 leads to a 2-fold higher anabolic effect than IGF-1. Researchers also noted that “LR3 IGF-I remained more potent than IGF-I in several of these effects even when the peptides were given.“[1]

The reduced affinity to IGF-1 binding proteins may also result in a shorter half-life of IGF-1 LR3 peptide. Animal suggest show that IGF-1 LR3 is eliminated within 4 hours.[2] At the same time, it may induce higher weight gain and organ mass increase in the tested animals compared to IGF-1.

The metabolites of IGF-1 LR3 may have a longer half-life and might remain detectable in test animals for up to 16 hours. In comparison, a high percentage of the natural IGF-1 appears to bind to IGF-1 binding proteins, which may reduce its effectiveness and prolongs half-life by up to 15 hours.[3]

According to one study in a mice model of muscular dystrophy, IGF-1 LR3peptide exposure appeared highly effective in reducing contraction-mediated injury.[4] Contraction damage is a major contributing factor to the pathophysiology of muscular dystrophy.

Another animal trial by Hill et al. also suggested that an IGF-1 LR3 exposure for 8 hours may have a protective effect against loss of muscle mass loss and muscle catabolism during periods of restricted energy intake and caloric deficit. The researchers reported that “Long(R3)-IGF-1 [exposure] tended to preserve whole-body and muscle protein in beef heifers on a low-quality diet.” The continuous exposure also led to significant suppression of the natural IGF-1 synthesis.[5]

One trial in guinea pigs also reported a significant increase in the organ weight of the animals after a 7-day exposure of IGF-1 LR3. The researchers note that the exposure most significantly enlarged the adrenals, gut, kidneys, and spleen.[6] It is important to note that IGF-1 LR3 and all other IGF-1 analogs are only hypothesized to mediate the anabolic effects of growth hormone.

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996 Jul;150(1):77-84. DOI: 10.1677/joe.0.1500077. PMID: 8708565.
  2. Mongongu C, Coudoré F, Domergue V, Ericsson M, Buisson C, Marchand A. Detection of LongR3 -IGF-I, Des(1-3)-IGF-I, and R3 -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal. 2021 Jul;13(7):1256-1269. DOI: 10.1002/dta.3016. Epub 2021 Feb 22. PMID: 33587816.
  3. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh). 1989 Dec;121(6):753-8. doi: 10.1530/acta.0.1210753. PMID: 2558477.
  4. Gehrig SM, Ryall JG, Schertzer JD, Lynch GS. Insulin-like growth factor-I analogue protects muscles of dystrophic MDX mice from contraction-mediated damage. Exp Physiol. 2008 Nov;93(11):1190-8. Doi: 10.1113/expphysiol.2008.042838. Epub 2008 Jun 20. PMID: 18567600.
  5. Hill RA, Hunter RA, Lindsay DB, Owens PC. Action of long(R3)-insulin-like growth factor-1 on protein metabolism in beef heifers. Domest Anim Endocrinol. 1999 May;16(4):219-29. doi: 10.1016/s0739-7240(99)00015-6. PMID: 10370861.
  6. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995 Aug;146(2):247-53. DOI: 10.1677/joe.0.1460247. PMID: 7561636.
  7. Kovacs GT, Worgall S, Schwalbach P, Steichele T, Mehls O, Rosivall L. Hypoglycemic effects of insulin-like growth factor-1 in experimental uremia: can concomitant growth hormone administration prevent this effect? Horm Res. 1999;51(4):193-200. doi: 10.1159/000023357. PMID: 10474022.
  8. MacDonald RS. The role of insulin-like growth factors in small intestinal cell growth and development. Horm Metab Res. 1999 Feb-Mar;31(2-3):103-13. DOI: 10.1055/s-2007-978706. PMID: 10226789.
  9. Dunaiski V, Dunshea FR, Walton PE, Goddard C. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. J Endocrinol. 1997 Dec;155(3):559-65. DOI: 10.1677/joe.0.1550559. PMID: 9488001.
  10. Martha S, Pantam N, Thungathurthi S, Rao VL, Devarakonda K. Study of insulin resistance in relation to serum IGF-I levels in subjects with different degrees of glucose tolerance. Int J Diabetes Dev Ctries. 2008 Apr;28(2):54-9. DOI: 10.4103/0973-3930.43100. PMID: 19902049; PMCID: PMC2772007.
Adipotide (FTPP) and Fat Cells

Adipotide (FTPP) and Fat Cells

by | Dec 15, 2022 | Research

Adipotide peptide is a synthetic peptidomimetic and an experimental proapoptotic compound known as FTPP (Fat-Targeted Proapoptotic Peptide). Peptidomimetics are synthetic molecules that may mimic a natural protein’s structural domain. Adipotide appears to bind to the protein receptor prohibitin, which is why it also bears the name Prohibitin-targeting peptide 1 (Prohibitin-TP01). By doing so, it has proapoptotic potential on adipose tissue, meaning that it may induce cell death in white fat cells. Animal studies suggest that by inducing targeted apoptosis, Adipotide peptide may induce fat loss and improvement in several metabolic parameters.

Featured Product

Adipotide FTPP (10mg)
 

Adipotide Peptide Overview

Adipotide FTPP appears to act by binding to the receptors for 2 specific proteins, ANXA2 (annexin A2) and prohibitin. Either of these receptors is expressed in various cells, but immunohistochemical analysis suggests that they form specific ANXA2-prohibitin receptor systems in white fat tissue.[1]

Research suggests that these receptors may play a role in regulating fatty acid transport in white adipose tissues.[2] Inhibiting the ANXA2 protein may lead to hypertrophy of white adipose cells due to reduced uptake of fatty acids.

On the other hand, prohibitin is a multifunctional membrane-associated protein that is thought to regulate cell survival and growth. It may trigger apoptosis by shuttling from the cell’s membrane to its nucleus.

Adipotide peptide has a unique structure consisting of the amino-acid sequence GKGGRAKDC-GG-D(KLAKLAK)2. The 9 amino acid sequence CKGGRAKDC appears to bear a specific affinity to the ANXA2-prohibitin receptor system found in the blood vessels supporting white adipose cells.[3] At the same time, (KLAKLAK)2 may disrupt mitochondrial membranes upon receptor-mediated cell internalization and induce programmed cell death.

As Adipotide peptide appears to bind to prohibitin in white adipose vasculature, it may trigger apoptosis and can result in the ablation of white fat cells.

According to research, Adipotide peptide and other similar peptidomimetics may potentially reduce subcutaneous and visceral fat and even target intra-organ fat, such as in fatty liver diseases.[4]

 

Research on Adipotide Peptide

Adipotide peptide may hold potential for two major research focuses –  obesity and cancer. Regarding its metabolic potential and the potential to induce fat loss, the peptidomimetic has been tested in mice, rats, and rhesus monkeys. In obese rats, 28 days of Adipotide peptide exposure led to a 30% reduction in body weight.[5] It also appeared to significantly suppress their appetite, even though the leptin levels of the animals plummeted. Furthermore, the energy expenditure of the animals was not apparently affected.

In another study, the researchers suggested that Adipotide peptide may have led to metabolic improvements as soon as the 3rd day of the study, even before there was a noticeable reduction in the body weight of the tested mice. Kim et al. concluded that Adipotide “rapidly and potently improved the glucose tolerance of obese mice in a weight- and food intake-independent manner.”[6] The peptidomimetic appeared to have reduced triglyceride and insulin levels as well.

In obese rhesus monkeys, Adipotide peptide exposure may have caused white adipose tissue blood vessels to undergo targeted apoptosis.[7] As a result, the tested animals lost weight and improved their insulin sensitivity within the first month of study. A significant decrease in white adipose tissue was noted by dual-energy x-ray absorptiometry and magnetic resonance imaging.

 

Adipotide Peptide and Prostate Cancer

The destruction of white fat may also have positive consequences for prostate cancer. This is suggested to be so, due to a high level of white fat that has been implicated as a critical contributing factor in poor prostate cancer outcomes.[8]

Studied have attempted to examine the impact of Adipotide peptide exposure in research models of prostate cancer. The study evaluated the action of a single cycle of Adipotide peptide in research models of castrate-resistant prostate cancer. According to the study, the models were put through the entire study cycle, but the study was terminated before completion.[9, 10]

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O’Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18637-42. doi: 10.1073/pnas.1114503108. Epub 2011 Nov 2. PMID: 22049339; PMCID: PMC3219136.
  2. Salameh A, Daquinag AC, Staquicini DI, An Z, Hajjar KA, Pasqualini R, Arap W, Kolonin MG. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016 Jul 7;1(10):e86351. doi: 10.1172/jci.insight.86351. PMID: 27468426; PMCID: PMC4959783.
  3. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004 Jun;10(6):625-32. doi: 10.1038/nm1048. Epub 2004 May 9. PMID: 15133506.
  4. Hossen N, Kajimoto K, Akita H, Hyodo M, Harashima H. A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. J Control Release. 2013 Oct 28;171(2):104-12. doi: 10.1016/j.jconrel.2013.07.013. Epub 2013 Jul 18. PMID: 23871959.
  5. Kim DH, Woods SC, Seeley RJ. Peptide designed to elicit apoptosis in adipose tissue endothelium reduces food intake and body weight. Diabetes. 2010 Apr;59(4):907-15. doi: 10.2337/db09-1141. Epub 2010 Jan 26. PMID: 20103704; PMCID: PMC2844838.
  6. Kim DH, Sartor MA, Bain JR, Sandoval D, Stevens RD, Medvedovic M, Newgard CB, Woods SC, Seeley RJ. Rapid and weight-independent improvement of glucose tolerance induced by a peptide designed to elicit apoptosis in adipose tissue endothelium. Diabetes. 2012 Sep;61(9):2299-310. doi: 10.2337/db11-1579. Epub 2012 Jun 25. PMID: 22733798; PMCID: PMC3425411.
  7. Barnhart KF, Christianson DR, Hanley PW, Driessen WH, Bernacky BJ, Baze WB, Wen S, Tian M, Ma J, Kolonin MG, Saha PK, Do KA, Hulvat JF, Gelovani JG, Chan L, Arap W, Pasqualini R. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011 Nov 9;3(108):108ra112. doi: 10.1126/scitranslmed.3002621. PMID: 22072637; PMCID: PMC3666164.
  8. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer: weighing the evidence. Eur Urol. 2013 May;63(5):800-9. doi: 10.1016/j.eururo.2012.11.013. Epub 2012 Nov 15. PMID: 23219374; PMCID: PMC3597763.
  9. Smith, T. L., Sidman, R. L., Arap, W., & Pasqualini, R. (2022). Targeting vascular zip codes: from combinatorial selection to drug prototypes. In The Vasculome (pp. 393-401). Academic Press.
  10. ClinicalTrials.gov [Internet]. National Library of Medicine (US). 2010 Dec 17 – . Identifier NCT01262664, A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity; 2019 Jan 4; http://clinicaltrials.gov/ct2/show/NCT01262664
Research in Wrinkle Reduction and Vialox

Research in Wrinkle Reduction and Vialox

by | Sep 23, 2022 | Research

Vialox peptide (also known as Pentapeptide-3V) has been suggested to exhibit potential in preventing muscle contraction by exhibiting a curare-like effect at the neuromuscular junction, disallowing the nervous system signals from reaching the muscles. Vialox peptide is of interest because of its potential to communicate between muscles and nerves.

Vialox peptide has been suggested to interfere with nerve and muscle signal transmission. Signals are transmitted in normal conditions after nerves release acetylcholine from their axons. Contraction may occur after acetylcholine transportation through the neuromuscular junction and binds to a receptor on the muscle.

Vialox peptide may halt contraction by binding to the AChR.[2] Acetylcholine is prevented from binding due to this action, which may induce less binding and fewer muscle contractions.

At the neuromuscular junction, sodium ion release is constrained due to acetylcholine binding to a muscle receptor. Depolarization occurs, which may cause electrical pulses to develop wrinkling and creasing via the muscle contraction. Vialox may inhibit this process by binding to AChR. Vialox peptide inhibits acetylcholine binding when it binds to AChR.

Vialox peptide has been suggested to only affect peripheral AChRs and may not affect central neuronal receptors. Unlike the other nicotinic acetylcholine receptor antagonists. This process suggests that Vialox only acts on the neuromuscular junction. Vialox peptide may potentially reduce skin texture in research cases by up to 11% and relief by 8%, according to one study. Since wrinkle size and ease are considered to be inversely proportional, Vialox may potentially reduce wrinkle development by an average of 8%. Approximately 60% and 47% of the animal subjects were studied.

Vialox (Pentapeptide-3V), composed of lysine, threonine, and serine, is considered to stimulate collagen production while tightening the skin by acting directly on the dermis. Vialox may potentially boost melanin production, a considered protectant against UV damage.

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Zhmak, M. N., Utkin, Y. N., Andreeva, T. V., Kudryavtsev, D. S., Kryukova, E. V., Tsetlin, V. I., … & Shelukhina, I. V. E. (2017). U.S. Patent No. 9,550,808. Washington, DC: U.S. Patent and Trademark Office.
  2. Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part II. Experimental dermatology, 21(8), 569-575. https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0625.2012.01527.x
Syn-Coll and Collagen Production Stimulation

Syn-Coll and Collagen Production Stimulation

by | Sep 21, 2022 | Research

Syn-coll peptide or Palmitoyl Tripeptide-5 is a peptide that has been hypothesized to increase the production of Type I and Type III collagen while inhibiting its degradation (1). It is also known as Palmitoyl Tripeptide-5 or Tripeptide-5. Syn-coll peptide appears to induce these functions by activating the transforming growth factor.

Research has suggested that Syn-coll may function similarly to Thrombospondin-1 by stimulating the breakdown of collagen caused by transforming growth factors. A naturally occurring peptide called TSP-1 is considered to promote TGF- activity. Syn-coll peptide is suggested to host the same properties as TSP-1 in increasing Type I and III collagen levels in dermal (skin) fibroblasts. According to experimental results, Syn-coll may raise type I and III collagen levels by 2-3 folds above normal levels(2). Varga et al. further suggest, ‘Our results indicate that TGF beta causes a marked enhancement of the production of types I and III collagens and fibronectin by cultured normal … dermal fibroblasts. The rate of collagen production by fibroblasts exposed to TGF beta was 2-3-fold greater than that of control cells. These effects were associated with a 2-3-fold increase in the steady-state amounts of types I and III collagen mRNAs and a 5-8-fold increase in the amounts of fibronectin mRNAs as determined by dot-blot hybridization with specific cloned cDNA probes. In addition, the increased production of collagen and fibronectin and the increased amounts of their corresponding mRNAs remained elevated for at least 72 h after the removal of TGF beta. These findings suggest that TGF beta may play a major role in the normal regulation of extracellular matrix production in vivo and may contribute to the development of pathological states of fibrosis’ (2) TSP-1 is a protein found in the extracellular matrix (ECM), and it is considered to be found alongside collagen and elastin.

Research regarding Palmitoyl Tripeptide-5, like TSP-1, suggests that this peptide may improve wound healing (3). It appears to participate in the development of skin structures. The Syn-coll peptide may inhibits matrix metalloproteinase I and III activity (MMP1 and MMP3). Enzymes that degrade collagen are known as matrix metalloproteinases. These enzymes may be beneficial because they recycle collagen, but appear uncontrollably increased to abnormal levels in conditions such as inflammation. As a result, premature skin damage, lines, and creasing along the skin structure may appear (3).

Syn-coll may potentially support the elimination of toxins and reduce the development and depth of wrinkles on the skin surface. Syn-coll appears to interact with the skin, keeping toxins at bay. This procedure may shield from free radicals.

By possibly inhibiting MMP1 and MMP3 activity, Syn-coll peptide may potentially help to prevent collagen breakdown. These hypotheses suggest that Syn-coll peptide may promote the formation of Type I and Type III collagen while inhibiting collagen breakdown by the enzymes, as mentioned earlier.

Syn-coll, a synthetic peptide component, has been hypothesized to have two primary effects. It appears to increase collagen production by replicating the activation of latent transforming growth factor beta, TGF (Tissue Growth Factor), considered a critical component in collagen synthesis. It appears to protect collagen from breakdown by inhibiting matrix metalloproteinases (MMP). Both activities may work together to keep the skin’s structural integrity intact. Compared to a placebo, Syn-coll peptide may be up to 3.5 times more impactful in wrinkle depth reduction. According to the researchers, Palmitoyl Tripeptide-5 may be 60% more effective than Palmitoyl Pentapeptide (5).

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 30;8:572923. doi: 10.3389/fchem.2020.572923.
  2. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987 Nov 1;247(3):597-604
  3. Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel). 2021 Jul 21;14(8):702. doi: 10.3390/ph14080702.
  4. Fadilah NIM, Rahman MBA, Yusof LM, Mustapha NM, Ahmad H. The Therapeutic Effect and In Vivo Assessment of Palmitoyl-GDPH on the Wound Healing Process. Pharmaceutics. 2021 Feb 1;13(2):193. doi: 10.3390/pharmaceutics13020193.
  5. Bucay VW, Day D. Adjunctive skin care of the brow and periorbital region. Clin Plast Surg. 2013 Jan;40(1):225-36. doi: 10.1016/j.cps.2012.09.003
  6. Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel). 2021 Jul 21;14(8):702. doi: 10.3390/ph14080702
Pal-GHK Peptide and Experimental Research in Wrinkle Depth

Pal-GHK Peptide and Experimental Research in Wrinkle Depth

by | Sep 19, 2022 | Research

Pal-GHK, also known as Palmitoyl Tripeptide-1 or Palmitoyl Oligopeptide, may act to mitigate the development of creasing in the epidermis and may regulate trans-epidermal water loss.[1,2] Pal-GHK is a peptide with a fatty acid end and a peptide end. Pal-GHK peptide is a fibroblast stimulant and a minor component of the elastin protein.

Featured Product

Buy Pal-GHK (Palmitoyl Tripeptide-1) (200mg)
 

Potential Function of Pal-GHK Peptide

Palmitoyl Tripeptide-1 may induce the production of fibroblasts at a rapid rate to replenish and regenerate any lost elastin. The GHK-end is connected to the Pal-end, the fatty acid (Palmitoyl) end of Pal-GHK acts as an intermediary. This transport complex appears to improve skin cell penetration.

Pal-GHK peptide appears to activate genes that may change and reset cells. This may be accomplished by attaching Palmitoyl to the peptide sequence, GHK, which may make it more effective for DNA repair genes and increases the expression of the 14 genes that modulate antioxidant production. Following the genetic changes, the action of cell aging may be reduced, as are radicals and toxic agents that cause the development of certain diseases.

Pal-GHK is a modified form of the extracellular matrix-derived peptide GHK that may potentially permeate the stratum corneum and attain the epidermal and dermal skin layers.

Pal-GHK (0.5 M) may increaase collagen synthesis in skin fibroblasts. It may reduce collagen degradation in skin samples exposed to UVA light when examined at a concentration of 6 ppm.

Scientists suggest that combined with the zwitterionic surfactant C12 dodecyl dimethylamine oxide they may investigate the composite’s identity into aggregates, ribbons, and nanobelts. Pal-GHK peptide as an internal standard helped quantify pal-KTTKS in anti-wrinkle creams using LC-MS/MS.

Scientists believe Pal-GHK peptide may activate age-related DNA repair and certain genes. According to new research, the peptide may potentially influence follicle regeneration.

 

Pal-GHK Peptide and Wrinkles

Pal-GHK may protect the extracellular matrix from certain cell aging consequences, according to scientific data[4]. Shagen et al report that “In a study … leading to statistically significant reductions in wrinkle length, depth and skin roughness. Another study applied both vehicle and palmitoyl tripeptide-1 to the skin … documenting a small but statistically significant increase in skin thickness (~4%, compared to the vehicle alone)The peptide accomplishes this by increasing the production of elastin and collagen.”

Palmitoyl Tripeptide-1 may replenish the skin’s extracellular matrix, reducing wrinkles, smoother skin, and less uneven skin. At the same time, it may protect collagen from degradation caused by Ultraviolet A (UVA) rays. Pal-GHK peptide may be examined solely or combinatorally with Palmitoyl tetrapeptide – Z.

 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing.  Bodily introduction of any sort is strictly prohibited by law.  All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References

  1. Ferreira, M. S., Magalhães, M. C., Sousa-Lobo, J. M., & Almeida, I. F. (2020). Trending anti-aging peptides. Cosmetics, 7(4), 91.
  2. Gorouhi, F., & Maibach, H. I. (2009). Role of peptides in preventing or treating aged skin. International journal of cosmetic science, 31(5), 327-345.
  3. Park, S. I., An, G. M., Kim, M. G., Heo, S. H., & Shin, M. S. (2020). Enhancement of Skin Permeation of Anti-wrinkle Peptide GHKs Using Cell Penetrating Peptides. Korean Chemical Engineering Research, 58(1), 29-35. https://doi.org/10.9713/KCER.2020.58.1.29